• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Pathologist onsite cuts repeat thyroid biopsies

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 5
Volume 32
Issue 5

Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.

Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.

University of North Carolina researchers compared 200 biopsies performed with a pathologist onsite and 200 with no pathologist present. All other factors being equal, 13.5% of biopsies performed without a pathologist onsite needed to be repeated, compared with only 5% where a pathologist was onsite, according to the research.

An inadequate sample is one where the pathologist deems there is an insufficient amount of tissue to make a diagnosis.

“We recommend that radiologists performing large numbers of thyroid biopsies use onsite pathology as it may reduce the need for repeat biopsy by up to 60%,” said Dr. Wui K. Chong, lead author of the study and an associate professor of radiology at UNC.

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.